Introduction
Schizophrenia is a severe and chronic mental disorder, mainly characterized by the presence of the so-called “positive” (delusions, hallucinations, disorganized thinking) and “negative” (anhedonia, blunted affect, social withdrawal) symptoms, as well as cognitive dysfunctions. Although several interrelated causes have been associated with the development of the pathology, it is generally accepted that the hyperfunction of dopaminergic and/or hypofunction of glutamatergic transmission (i.e., the so-called “combined glutamate/dopamine hypothesis of schizophrenia”) might underlie the symptoms of schizophrenia (Howes et al., 2015; Snyder and Gao, 2020). Clinical indications demonstrate that positive symptoms respond well to conventional antipsychotic medications, which mainly act as dopamine D2 receptor (D2R) antagonists, while negative symptoms and cognitive impairments are more difficult to be counteracted. Several non-D2R related mechanisms of action of antipsychotic drugs have been proposed over the last decades, but none has conclusively been proven effective. Furthermore, while the newer antipsychotic drugs produce fewer motor side effects than conventional “first generation” drugs, safety and tolerability concerns about weight gain and endocrinopathies often limit their use (Li et al., 2016). Thus, there is an urgent necessity for more effective and better-tolerated antipsychotic drugs, as well as to identify new molecular targets and develop mechanistically novel compounds that can address the various symptom dimensions of schizophrenia. Due to the complexity of the pathology, it seems likely, however, that a multi-target strategy, i.e., the use of multifunctional drugs or a combination of drugs affecting distinct targets, will lead to more effective therapeutic approaches.
Based on this background and recent findings, the present opinion paper was conceived to critically review possible interactions between adenosine and kynurenic acid (KYNA) in this context. These two neuromodulators may be pathophysiologically associated with schizophrenia, and a deeper understanding of their interactions may lead to the development of innovative strategies for the treatment of schizophrenia.
Adenosine and Schizophrenia
It is well recognized that, beside dopamine and glutamate systems, the purinergic system may be also involved in the pathophysiology of schizophrenia (Lara and Souza, 2000; Krügel, 2016; ). In fact, the so-called “adenosine hypothesis of schizophrenia” (Lara et al., 2006; ; Hirota and Kishi, 2013; Rial et al., 2014) postulates that a reduced adenosine tone is involved in the dysregulation of glutamatergic and dopaminergic activity in schizophrenia patients. Accordingly, based on informative studies in experimental animals, adenosine receptor agonists may act as atypical antipsychotic drugs (Krügel, 2016).
Adenosine A2A receptors (A2ARs), which are highly expressed in the striatum and the olfactory tubercle, exert fine regulation of individual synapses (Hines and Haydon, 2014; Krügel, 2016), and their activation facilitates glutamate release and potentiates N-methyl-D-aspartate (NMDA) receptor function. As a consequence, A2ARs regulate synaptic plasticity by promoting adequate (or aberrant) adaptive responses in neuronal circuits (; ; Krügel, 2016). In general, adenosine and A2AR agonists induce behavioral effects similar to those of dopamine receptor (DR) antagonists used as antipsychotics (Rimondini et al., 1997; Wardas, 2008; Shen et al., 2012; ). In fact, A2AR agonists inhibit hyperlocomotion and sensorimotor gating deficits induced by DR agonists and/or NMDA receptor channel blockers in rodents (Krügel, 2016). More specifically, converging evidence suggests that heteroreceptor complexes containing AR and DR protomers, especially adenosine A2AR-D2R heteroreceptor complexes, exert strong inhibitory modulation of dorsal and ventral striato-pallidal GABA neurons (; Fuxe et al., 2008; ; ). Thus, A2AR agonists reduce D2R recognition and function by acting on the A2A-D2 heteroreceptor complexes located in the dorsal and ventral striato-pallidal anti-reward GABA pathway. Upon activation of this pathway, the brain circuit involved increases the glutamate drive to the frontal cortex from the medial dorsal thalamic nucleus, and transfer of anti-reward information takes place (Fuxe et al., 2008; ; ; ). Thus, it was suggested more than a decade ago (Fuxe et al., 2008) and recently demonstrated (; Valle-León et al., 2020) that drugs promoting A2AR-D2R heteromer formation might constitute an alternative strategy for the treatment of schizophrenia. Furthermore, A2AR agonists can allow a reduction of the dose of the D2R antagonists which should reduce the side effects of classical and atypical antipsychotic drugs. These findings moved A2AR agonists into the focus of interest for adenosinergic therapeutic options in the disease.
The adenosine A1 receptor (A1R), too, has been proposed as a potential antipsychotic drug target (Ossowska et al., 2020). A1Rs are coupled to the Gi/o family of G-proteins, are abundantly present throughout the central nervous system, and appear to generally exert an inhibitory and neuroprotective ‘tone’ (; Krügel, 2016). Activation of presynaptic A1Rs inhibits the release of neurotransmitters (e.g., glutamate, GABA, dopamine, serotonin and acetylcholine) and depresses postsynaptic neuronal signaling by inducing hyperpolarization (Paul et al., 2011). Notably, pre- and post-synaptic A1R activation, leading to reduced glutamate and GABA release as well as impaired NMDA receptor and D1R function, respectively, plays a major role in the “adenosine hypothesis” of schizophrenia (Fuxe et al., 2008; Krügel, 2016). Thus, as the pathophysiologically significant NMDA receptor hypofunction in the disease can be traced mainly to fast-spiking GABA neurons (Nakazawa and Sapkota, 2020), a reduction of A1R signaling should benefit critical neuronal circuits and consequently have positive effects on schizophrenia symptoms. In line with this view, A2AR agonists might exert part of their antipsychotic action by activating the A2AR protomer in a prejunctional A1-A2A receptor complex. Through this antagonistic receptor-receptor interaction, A2AR agonists could lower the affinity of the A1R protomer and thus the inhibitory action of the A1R protomer on glutamate release (; Franco et al., 2008; ). Antagonists of A1R receptors have indeed been shown to reduce memory impairment in experimental animals ().
On the other hand, since activation of A1Rs on dopaminergic nerve terminals inhibits dopamine release (Paul et al., 2011; Zhang and Sulzer, 2012), A1R agonists, too, may counteract schizophrenia symptoms. In fact, preclinical findings have indicated that stimulation of A1Rs may have antipsychotic effects, although cognitive dysfunctions must be expected to be associated with the treatment (Ossowska et al., 2020). Specifically, recent studies demonstrated that the selective A1R agonist 5-Chloro-5′-deoxy-N6-(±)-(endo-norborn-2-yl)adenosine (5′-Cl-5′-deoxy-ENBA) reduces the hyperlocomotion caused by amphetamine or the non-competitive NMDA receptor antagonist dizolcipine (MK-801; ; Ossowska et al., 2020). Inhibition of amphetamine- and MK-801-mediated hyperlocomotion may also be caused by allosteric interaction of D1R signaling in the A1R-D1R heteroreceptor complex, which is located in striato-nigral and striato-entopeduncular GABA neurons as well as in D1R-rich GABA neurons in the nucleus accumbens (Rimondini et al., 1997; Fuxe et al., 2007; Fuxe et al., 2008; Fuxe et al., 2020; Franco et al., 2008; Pérez-de-la-Mora et al., 2020).
Kynurenic Acid and Schizophrenia
KYNA, an astrocyte-derived neuromodulator, has been repeatedly linked to the cognitive deficits that are observed in individuals with schizophrenia. KYNA is a metabolite of the kynurenine pathway (KP), which accounts for more than 90% of the degradation of the essential amino acid tryptophan (). Through a series of enzymatic steps, the evolutionarily preserved KP generates not only KYNA but also a considerable number of other biologically active compounds, several of which play increasingly appreciated roles in brain physiology and pathology (Schwarcz et al., 2012). KYNA is produced directly from the pivotal KP metabolite kynurenine, either by oxidation (Ramos-Chávez et al., 2018) or by irreversible transamination by kynurenine aminotransferases (KATs; Guidetti et al., 2007). These enzymes are preferentially localized in astrocytes, which promptly release newly formed KYNA into the extracellular compartment (Turski et al., 1989; Guidetti et al., 2007). Though other molecular targets may be of relevance as well, the neurobiological effects of endogenous KYNA are mediated primarily through its actions as an antagonist of both the NMDA and the α7nAChR function, i.e. two receptors that are critically involved in cognitive processes (Moroni et al., 2012; Stone et al., 2013; Phenis et al., 2020). Consequently, as shown consistently in experimental animals, elevated brain KYNA levels are associated with a number of cognitive deficits, such as impairments in contextual learning and memory and abnormal visuospatial working memory (Schwarcz et al., 2012; Muneer, 2020). These effects are likely related to the fact that even relatively small fluctuations in KYNA levels bi-directionally affect the extracellular levels of neurotransmitters that play major roles in cognitive functions, including dopamine, acetylcholine, glutamate and GABA (Wu et al., 2007; Zmarowski et al., 2009; Konradsson-Geuken et al., 2010; ). Notably, selective pharmacological inhibition of KYNA formation has been shown to have pro-cognitive effects in several established animal models (Kozak et al., 2014; Pocivavsek et al., 2019).
The observation that KYNA concentrations are significantly elevated in cortical brain regions and cerebrospinal fluid of individuals afflicted with schizophrenia (; Schwarcz et al., 2001; Nilsson et al., 2005; Sathyasaikumar et al., 2011; Linderholm et al., 2012) raised the possibility that KYNA may be causally involved in the cognitive dysfunctions seen in these patients (cf. reviews by Wonodi and Schwarcz, 2010; ; Plitman et al., 2017; Muneer, 2020). This hypothesis is compatible with the fact that the expression of KYNA’s key biological targets (i.e., NMDA receptors and α7nAChRs) was found to be reduced in the brain of patients with schizophrenia (Guan et al., 1999; Young and Geyer, 2013; Hu et al., 2015). Together with the insights gained from the pre-clinical studies, these findings suggest that interventions leading to a decrease in brain KYNA may constitute a useful strategy for effecting cognitive improvement in the clinical population.
Adenosine and Kynurenic Acid Interactions: Are They Relevant for Schizophrenia Treatments?
Although neurobiological properties of adenosine may be linked to KYNA, interactions between the adenosine system and the KP have not been carefully examined so far. However, in an in vivo microdialysis study performed in rats, local perfusion of adenosine was shown to rapidly and concentration-dependently raise extracellular KYNA levels in the striatum (Wu et al., 2004). Interestingly, this effect was mimicked by perfusion of the A1R agonist N6-cyclopentyladenosine (CPA), whereas the selective A2AR agonist 2-p-(2-carboxyethyl) phenylethylamino-5′-N-ethylcarboxamidoadenosine hydrochloride (CGS-21680) was ineffective. Furthermore, local perfusion of the A1R antagonist 8-cyclopentyltheophylline (CPT) attenuated the effect of adenosine on extracellular KYNA levels. As the effect of adenosine on KYNA was not observed in the excitotoxically lesioned, i.e., neuron-depleted, striatum, it appears that neuronal A1R activation influences glial KYNA synthesis indirectly (Wu et al., 2004).
While A2AR activation does not appear to affect KYNA levels in the brain under physiological conditions, it is noteworthy that A2ARs not only interact physically with D2Rs (see above) but also with the NMDAR (; Liu et al., 2006). An A2AR agonist may therefore inhibit the activity of the D2R protomer both in the A2AR-D2R heteromer () and in a putative A2AR-D2R-NMDAR heteromer, and thereby indirectly enhance NMDAR activity. By this mechanism, A2AR stimulation could counteract and reduce the cognitive dysfunction caused by the elevated brain levels of the endogenous NMDAR antagonist KYNA in pathological situations (e.g., schizophrenia).
Furthermore, based on the postulated action of A2AR agonists on prejunctional A1-A2A heteroreceptor complexes (), it also seems possible that A2AR agonists, in addition to inhibition of D2R signaling, cause a reduction in KYNA levels by allosteric inhibition of A1R signaling. In view of the study of Wu et al. (2004); see above), this mechanism, too, may only operate under pathological conditions.
Taken together, these phenomena may have implications for the proposed use of adenosine receptor agonists in the treatment of schizophrenia (). Thus, the beneficial antipsychotic effects of A1R agonists, which are predicted from studies in experimental animals (; Ossowska et al., 2020), may also result in cognitive deficits due to a A1R-induced increase in KYNA levels. Co-treatment with drugs that are able to reduce brain KYNA levels may therefore ameliorate the untoward side effects of A1R agonists. Inhibitors of kynurenine aminotransferase II (KAT II), the principal enzyme responsible for the synthesis of rapidly mobilizable KYNA in the mammalian brain (Guidetti et al., 2007), deserve particular attention in this context (Rossi et al., 2010; Nematollahi et al., 2016; Plitman et al., 2017; ). Notably, the beneficial effects of KAT II inhibitors may be further enhanced by A2AR agonists and may also improve negative symptoms in schizophrenia patients via allosteric inhibition of D2R signaling in A2AR-D2R heteroreceptor complexes of ventral striatal-pallidal GABA neurons ().
Conclusion
The considerations outlined here indicate a possible relevance of adenosine and KYNA interactions in the pathophysiology and treatment of schizophrenia, and emphasize the need to investigate this issue in detail in future preclinical studies. Specifically, the effects of combined approaches with adenosine receptor ligands and compounds able to reduce brain KYNA levels (e.g., KAT II inhibitors) have not been assessed experimentally so far. Hypothesis testing in rats that were prenatally exposed to kynurenine, which have deficits resembling several of the cognitive impairments seen in schizophrenia patients (Hahn et al., 2018), may be particularly informative for this purpose. These studies may support the development of new multi-target therapeutic strategies that focus on both the purinergic system, especially in relation to adenosine receptor containing heteroreceptor complexes, and brain KYNA function.
Statements
Author contributions
LF, DOB-E, TC, and PD performed the literature review. MZ, KF, and RS helped to synthesize data and edited the text. SB reviewed the information and edited the text.
Funding
This work was supported by a grant from the University of Ferrara (FAR 2019) to LF, USPHS grant MH103222 (Silvio O. Conte Center for Translational Mental Health Research) to RS and a Swedish Research Council grant (04X-715, 2020–2022) to KF.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AgnatiL. F.FerréS.BurioniR.WoodsA.GenedaniS.FrancoR.et al (2005). Existence and theoretical aspects of homomeric and heteromeric dopamine receptor complexes and their relevance for neurological diseases. Neuromolec. Med.7, 61–78. 10.1385/NMM:7:1-2:061
2
AzdadK.GallD.WoodsA. S.LedentC.FerréS.SchiffmannS. N. (2009). Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology34, 972–986. 10.1038/npp.2008.144
3
BeggiatoS.AntonelliT.TomasiniM. C.TanganelliS.FuxeK.SchwarczR.et al (2013). Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo. Eur. J. Neurosci.37, 1470–1477. 10.1111/ejn.12160
4
Blanco-AyalaT.SathyasaikumarK. V.UysJ. D.Pérez-de-la-CruzV.PiduguL. S.SchwarczR. (2020). N-Acetylcysteine inhibits kynurenine aminotransferase II. Neuroscience444, 160–169. 10.1016/j.neuroscience.2020.07.049
5
BoisonD.AronicaE. (2015). Comorbidities in neurology: is adenosine the common link?. Neuropharmacology97, 18–34. 10.1016/j.neuropharm.2015.04.031
6
BoisonD.SingerP.ShenH.-Y.FeldonJ.YeeB. K. (2012). Adenosine hypothesis of schizophrenia - opportunities for pharmacotherapy. Neuropharmacology62, 1527–1543. 10.1016/j.neuropharm.2011.01.048
7
Borroto-EscuelaD. O.CarlssonJ.AmbroginiP.NarváezM.WydraK.TarakanovA. O.et al (2017). Understanding the role of GPCR heteroreceptor complexes in modulating the brain networks in health and disease. Front. Cell Neurosci.11, 37. 10.3389/fncel.2017.00037
8
Borroto-EscuelaD. O.FerraroL.NarvaezM.TanganelliS.BeggiatoS.LiuF.et al (2020). Multiple adenosine-dopamine (A2A-D2 Like) heteroreceptor complexes in the brain and their role in schizophrenia. Cells9, 1077. 10.3390/cells9051077
9
Borroto-EscuelaD. O.FuxeK. (2019). Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson's disease and its treatment. J. Neural Transm.126, 455–471. 10.1007/s00702-019-01969-2
10
Borroto-EscuelaD. O.WydraK.FilipM.FuxeK. (2018). A2AR-D2R heteroreceptor complexes in cocaine reward and addiction. Trends Pharmacol. Sci.39, 1008–1020. 10.1016/j.tips.2018.10.007
11
CervenkaI.AgudeloL. Z.RuasJ. L. (2017). Kynurenines: tryptophan's metabolites in exercise, inflammation, and mental health. Science357 (6349), eaaf9794. 10.1126/science.aaf9794
12
ChefferA.CastilloA. R. G.Corrêa-VellosoJ.GonçalvesM. C. B.NaaldijkY.NascimentoI. C.et al (2018). Purinergic system in psychiatric diseases. Mol. Psychiatry23, 94–106. 10.1038/mp.2017.188
13
ChenJ.-F.LeeC.-f.ChernY. (2014). Adenosine receptor neurobiology: overview. Int. Rev. Neurobiol.119, 1–49. 10.1016/B978-0-12-801022-8.00001-5
14
CiruelaF.CasadoV.RodriguesR. J.LujanR.BurguenoJ.CanalsM.et al (2006). Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci.26, 2080–2087. 10.1523/JNEUROSCI.3574-05.2006
15
ErhardtS.BlennowK.NordinC.SkoghE.LindströmL. H.EngbergG. (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett.313, 96–98. 10.1016/s0304-3940(01)02242-x
16
ErhardtS.SchwielerL.ImbeaultS.EngbergG. (2017). The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology112, 297–306. 10.1016/j.neuropharm.2016.05.020
17
EyjolfssonE. M.BrennerE.KondziellaD.SonnewaldU. (2006). Repeated injection of MK801: an animal model of schizophrenia?Neurochem. Int.48, 541–546. 10.1016/j.neuint.2005.11.019
18
FerréS.Von EulerG.JohanssonB.FredholmB. B.FuxeK. (1991). Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U.S.A.88, 7238–7241. 10.1073/pnas.88.16.7238
19
FrancoR.CasadóV.CortésA.Pérez-CapoteK.MallolJ.CanelaE.et al (2008). Novel pharmacological targets based on receptor heteromers. Brain Res. Rev.58, 475–482. 10.1016/j.brainresrev.2008.06.002
20
FuxeK.FerréS.GenedaniS.FrancoR.AgnatiL. F. (2007). Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol. Behav.92, 210–217. 10.1016/j.physbeh.2007.05.034
21
FuxeK.MarcellinoD.RiveraA.Diaz-CabialeZ.FilipM.GagoB.et al (2008). Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res. Rev.58, 415–452. 10.1016/j.brainresrev.2007.11.007
22
GuanZ.-Z.ZhangX.BlennowK.NordbergA. (1999). Decreased protein level of nicotinic receptor α7 subunit in the frontal cortex from schizophrenic brain. Neuroreport10, 1779–1782. 10.1097/00001756-199906030-00028
23
GuidettiP.HoffmanG. E.Melendez-FerroM.AlbuquerqueE. X.SchwarczR. (2007). Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia55, 78–92. 10.1002/glia.20432
24
HahnB.ReneskiC. H.PocivavsekA.SchwarczR. (2018). Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood. Psychopharmacology235, 651–661. 10.1007/s00213-017-4780-9
25
HinesD. J.HaydonP. G. (2014). Astrocytic adenosine: from synapses to psychiatric disorders. Phil. Trans. R. Soc. B369, 20130594. 10.1098/rstb.2013.0594
26
HirotaT.KishiT. (2013). Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophrenia Res.149, 88–95. 10.1016/j.schres.2013.06.038
27
HowesO.McCutcheonR.StoneJ. (2015). Glutamate and dopamine in schizophrenia: an update for the 21st century. J. Psychopharmacol.29, 97–115. 10.1177/0269881114563634
28
HuW.MacDonaldM. L.ElswickD. E.SweetR. A. (2015). The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann. N.Y. Acad. Sci.1338, 38. 10.1111/nyas.12547
29
Konradsson-GeukenÅ.WuH. Q.GashC. R.AlexanderK. S.CampbellA.SozeriY.et al (2010). Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience169, 1848–1859. 10.1016/j.neuroscience.2010.05.052
30
KozakR.CampbellB. M.StrickC. A.HornerW.HoffmannW. E.KissT.et al (2014). Reduction of brain kynurenic acid improves cognitive function. J. Neurosci.34, 10592–10602. 10.1523/JNEUROSCI.1107-14.2014
31
KrügelU. (2016). Purinergic receptors in psychiatric disorders. Neuropharmacology104, 212–225. 10.1016/j.neuropharm.2015.10.032
32
LaraD. R.Dall'IgnaO. P.GhisolfiE. S.BrunsteinM. G. (2006). Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuro-Psychopharmacology Biol. Psychiatry30, 617–629. 10.1016/j.pnpbp.2006.02.002
33
LaraD. R.SouzaD. O. (2000). Schizophrenia: a purinergic hypothesis. Med. Hypotheses54, 157–166. 10.1054/mehy.1999.0003
34
LiP.L. SnyderG.E. VanoverK. (2016). Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Ctmc16, 3385–3403. 10.2174/1568026616666160608084834
35
LinderholmK. R.SkoghE.OlssonS. K.DahlM.-L.HoltzeM.EngbergG.et al (2012). Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophrenia Bull.38, 426–432. 10.1093/schbul/sbq086
36
LiuX.-Y.ChuX.-P.MaoL.-M.WangM.LanH.-X.LiM.-H.et al (2006). Modulation of D2R-NR2B interactions in response to cocaine. Neuron52, 897–909. 10.1016/j.neuron.2006.10.011
37
MoroniF.CozziA.SiliM.MannaioniG. (2012). Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J. Neural Transm.119, 133–139. 10.1007/s00702-011-0763-x
38
MuneerA. (2020). Kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: pathophysiologic and therapeutic considerations. Clin. Psychopharmacol. Neurosci.18, 507–526. 10.9758/cpn.2020.18.4.507
39
NakazawaK.SapkotaK. (2020). The origin of NMDA receptor hypofunction in schizophrenia. Pharmacol. Ther.205, 107426. 10.1016/j.pharmthera.2019.107426
40
NematollahiA.SunG.JayawickramaG.ChurchW. (2016). Kynurenine aminotransferase isozyme inhibitors: a review. Int. J. Mol. Sci.17, 946. 10.3390/ijms17060946
41
NilssonL. K.LinderholmK. R.EngbergG.PaulsonL.BlennowK.LindströmL. H.et al (2005). Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophrenia Res.80, 315–322. 10.1016/j.schres.2005.07.013
42
OssowskaK.KosmowskaB.WardasJ. (2020). Potential antipsychotic action of the selective agonist of adenosine A1 receptors, 5′-Cl-5′-deoxy-ENBA, in amphetamine and MK-801 rat models. Pharmacol. Rep.72, 580–588. 10.1007/s43440-020-00093-3
43
PaulS.ElsingaP. H.IshiwataK.DierckxR. A.van WaardeA. (2011). Adenosine A1 receptors in the central nervous system: their functions in health and disease, and possible elucidation by PET imaging. Curr. Med. Chem.18, 4820. 10.2174/092986711797535335
44
Pérez de la MoraM.Hernandez-MondragonC.Crespo-RamirezM.Rejon-OrantesJ.Borroto-EscuelaD. O.FuxeK. (2020). Conventional and novel pharmacological approaches to treat dopamine-related disorders: focus on Parkinson's disease and schizophrenia. Neuroscience439, 301–318. 10.1016/j.neuroscience.2019.07.026
45
PhenisD.VunckS. A.ValentiniV.AriasH.SchwarczR.BrunoJ. P. (2020). Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task. Psychopharmacology237, 1723–1735. 10.1007/s00213-020-05495-y
46
PlitmanE.IwataY.CaravaggioF.NakajimaS.ChungJ. K.GerretsenP.et al (2017). Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull.43, 764–777. 10.1093/schbul/sbw221
47
PocivavsekA.ElmerG. I.SchwarczR. (2019). Inhibition of kynurenine aminotransferase II attenuates hippocampus-dependent memory deficit in adult rats treated prenatally with kynurenine. Hippocampus29, 73–77. 10.1002/hipo.23040
48
Ramos-ChávezL. A.Lugo HuitrónR.González EsquivelD.PinedaB.RíosC.Silva-AdayaD.et al (2018). Relevance of alternative routes of kynurenic acid production in the brain. Oxid. Med. Cell. Longev.2018, 1. 10.1155/2018/5272741
49
RialD.LaraD. R.CunhaR. A. (2014). The adenosine neuromodulation system in schizophrenia. Int. Rev. Neurobiol.119, 395–449. 10.1016/B978-0-12-801022-8.00016-7
50
RimondiniR.FerréS.ӦgrenS. O.FuxeK. (1997). Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology17, 82–91. 10.1016/S0893-133X(97)00033-X
51
RossiF.ValentinaC.GaravagliaS.SathyasaikumarK. V.SchwarczR.KojimaS.-I.et al (2010). Crystal structure-based selective targeting of the pyridoxal 5′-phosphate dependent enzyme kynurenine aminotransferase II for cognitive enhancement. J. Med. Chem.53, 5684–5689. 10.1021/jm100464k
52
SathyasaikumarK. V.StachowskiE. K.WonodiI.RobertsR. C.RassoulpourA.McMahonR. P.et al (2011). Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophrenia Bull.37, 1147–1156. 10.1093/schbul/sbq112
53
SchwarczR.BrunoJ. P.MuchowskiP. J.WuH.-Q. (2012). Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci.13, 465–477. 10.1038/nrn3257
54
SchwarczR.RassoulpourA.WuH.-Q.MedoffD.TammingaC. A.RobertsR. C. (2001). Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry50, 521–530. 10.1016/s0006-3223(01)01078-2
55
ShenH.-Y.SingerP.LytleN.WeiC. J.LanJ.-Q.Williams-KarneskyR. L.et al (2012). Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. J. Clin. Invest.122, 2567–2577. 10.1172/JCI62378
56
SnyderM. A.GaoW.-J. (2020). NMDA receptor hypofunction for schizophrenia revisited: perspectives from epigenetic mechanisms. Schizophrenia Res.217, 60–70. 10.1016/j.schres.2019.03.010
57
StoneT. W.StoyN.DarlingtonL. G. (2013). An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci.34, 136–143. 10.1016/j.tips.2012.09.006
58
TurskiW. A.GramsbergenJ. B. P.TraitlerH.SchwarczR. (1989). Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J. Neurochem.52, 1629–1636. 10.1111/j.1471-4159.1989.tb09218.x
59
Valle-LeónM.CalladoL. F.AsoE.Cajiao-ManriqueM. M.SahlholmK.López-CanoM.et al (2020). Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia. Neuropsychopharmacology46, 665–672. 10.1038/s41386-020-00872-9
60
WardasJ. (2008). Potential role of adenosine A2A receptors in the treatment of schizophrenia. Front. Biosci.13, 4071–4096. 10.2741/2995
61
WonodiI.SchwarczR. (2010). Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophrenia Bull.36, 211–218. 10.1093/schbul/sbq002
62
WuH.-Q.FuxeK.SchwarczR. (2004). Neuronal A1 receptors mediate increase in extracellular kynurenic acid after local intrastriatal adenosine infusion. J. Neurochem.90, 621–628. 10.1111/j.1471-4159.2004.02531.x
63
WuH.-Q.RassoulpourA.SchwarczR. (2007). Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?J. Neural Transm.114, 33–41. 10.1007/s00702-006-0562-y
64
YoungJ. W.GeyerM. A. (2013). Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem. Pharmacol.86, 1122–1132. 10.1016/j.bcp.2013.06.031
65
ZhangH.SulzerD. (2012). Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors. Basal Ganglia2, 5–13. 10.1016/j.baga.2011.11.004
66
ZmarowskiA.WuH.-Q.BrooksJ. M.PotterM. C.PellicciariR.SchwarczR.et al (2009). Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur. J. Neurosci.29, 529–538. 10.1111/j.1460-9568.2008.06594.x
Summary
Keywords
adenosine A1 and A2A receptors, cognition, combinatory therapy, kynurenine pathway, receptor heteromers
Citation
Beggiato S, Zuccarini M, Cassano T, Borroto-Escuela DO, Di Iorio P, Schwarcz R, Fuxe K and Ferraro L (2021) Adenosine and Kynurenic Acid Interactions: Possible Relevance for Schizophrenia Treatment?. Front. Pharmacol. 12:654426. doi: 10.3389/fphar.2021.654426
Received
20 January 2021
Accepted
03 March 2021
Published
14 April 2021
Volume
12 - 2021
Edited by
Nikolaos Pitsikas, University of Thessaly, Greece
Reviewed by
Ana Carolina Issy, University of São Paulo, Brzil
Katerina Antoniou, University of Ioannina, Greece
Updates
Copyright
© 2021 Beggiato, Zuccarini, Cassano, Borroto-Escuela, Di Iorio, Schwarcz, Fuxe and Ferraro.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sarah Beggiato, sarah.beggiato@unich.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.